Barclays lowered the firm's price target on Alvotech to $4 from $5 and keeps an Underweight rating on the shares. The firm expects the shares to "remain in a holding pattern" pending U.S. approvals in Q4. Alvotech's financial flexibility "bears watching" given its high leverage, the analyst tells investors in a research note.
